Straits Times Index
3,084.70 +18.76 (+0.61%) S&P 500
4,554.89 +4.46 (+0.10%) Dow
35,416.98 +83.51 (+0.24%) Nasdaq
14,281.76 +40.73 (+0.29%) Bitcoin USD
38,246.93 +1,059.99 (+2.85%) CMC Crypto 200
789.82 +25.13 (+3.29%)
Vyant Bio, Inc. (VYNT)
| Previous close | 0.1775 |
| Open | 0.1800 |
| Bid | 0.0000 x 900 |
| Ask | 0.0000 x 1800 |
| Day's range | 0.1775 - 0.1800 |
| 52-week range | 0.1410 - 1.5800 |
| Volume | |
| Avg. volume | 22,250 |
| Market cap | 1.123M |
| Beta (5Y monthly) | 0.43 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Vyant Bio Provides Update on Winddown Activities
CHERRY HILL, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT) is providing an update to shareholders regarding its winddown activities pursuant to its Plan of Liquidation and Dissolution following the sale of substantially all of its assets. Vyant Bio’s Board of Directors currently anticipates that it will file a Certificate of Dissolution with the State of Delaware in late December 2023, after which the Company’s common stock will cease to trade and
- GlobeNewswire
Vyant Bio Announces Stockholder Approval of Plan of Dissolution
CHERRY HILL, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT) is announcing the results of its special meeting of stockholders on November 1, 2023 (the “Special Meeting”). At the Special Meeting, Vyant Bio’s stockholders, upon the unanimous recommendation of Vyant Bio’s board of directors, voted in favor of the proposal to approve the voluntary liquidation and dissolution of the Company, pursuant to a Plan of Liquidation and Dissolution (the “Dissolu
- GlobeNewswire
Vyant Bio Announces Completion of StemoniX Asset Sale
CHERRY HILL, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT) announced that it has completed the sale of all or substantially all of the assets of the Company (the “Sale”) pursuant to an Asset Purchase Agreement dated July 13, 2023. ABOUT VYANT BIO, INC. Vyant Bio, Inc. (OTC: VYNT) has no continuing operating activities other than the winddown and closure of its business. The Company is currently seeking to obtain its shareholders’ approval for the
